New epilepsy drugs! The new fine-particle preparation sinnuse of Fycompa (Weiketai ®, LulenPanai) is on the market in Japan, and the tablets are on the market in China in January!

July 12, 2020 // Eisai recently announced the launch of the anti-epileptic drug Fycompa (Weketai®, generic name: perampanel, perlumpanay, 1%, 100 grams per bottle) new fine particle preparationsapproved in January this year, the drug will make it easier for children and adults with difficulty taking tablets to take FycompaFycompa has a variety of dosage forms, the drug is taken orally once a day before bedtime, and its oral liquid suspensions and tablets have been approved in the United States and EuropeFycompa is an anti-epileptic drug (AEDs) developed in-house by Ae-class, a highly selective, non-competitive AMPA glutamate receptor antagonistglutamate is the main neurotransmitter for mediatuating seizuresas an AMPA receptor antagonist, Fycompa reduces overexcitement among neurons associated with seizures by targeting post-synaptic AMPA receptor-glutamate activity;to date, Fycompa has been approved in more than 65 countries worldwide, including Japan, the United States, China, and other countries in Europe and Asia, as an adjuvant therapy for the treatment of partial seizures (POS, with or without secondary systemic seizures) in patients 12 years of age and older, Fycompa has been approved in more than 60 countries worldwide, including the United States, Japan, Europe and Asia, as an adjuvant therapy for the treatment of pregencytic acute direct alclampsia (PGTC) seizures in patients 12 years and olderin the United States and Japan, Fycompa is also used as a single drug and as an auxiliary therapy for the treatment of partial seizures (with or without secondary systemic epilepsy) in patients 4 years of age and olderin Europe, Aishi has submitted an application for additional approval from Fycompa as an auxiliary therapy for pediatric patients with epilepsy to treat partial seizures (with or without secondary systemic seizures) or primary all-out direct seizures (PGTC) seizuresto date, Fycompa has been used to treat more than 300,000 patients worldwidecurrently, Aishi is also conducting a global Phase III clinical study (Study 338) to evaluate Fycompa's treatment for epilepsy associated with Lennox-Gastaut syndrome, the company is also developing an injection agent for Fycompain China, Fycompa (®, generic name: perampanel, Erlumpanai) submitted a new drug application (NDA) in September 2018 as an assistive therapy for the treatment of partial seizures in patients 12 years and olderThe State Drug Administration of China (NMPA) granted Fycompa priority review status in January 2019 and approved Fycompa in September 2019 due to its significant clinical benefits to existing drugsin early January this year, The Issing introduced Fycompa (Weektai ®), a daily tablet for partial seizure systolic epilepsy (accompanied or non-accompanied) of epilepsy patients aged 12 and overestimates that there are about 9 million epilepsy patients in China, about 60% of which are affected by partial seizures, of which 40% require assisted treatment about 30% of people with epilepsy receive market-available anti-epileptic drugs (AEDs) that cannot control seizures, there is a significant lying unmet medical need in this area epilepsy can be roughly classified according to its type of seizures, of which partial seizures account for about 60% of seizurecases, systemic seizures accountfored at about 40% primary, all-severe direct-tofew (PGTC) seizures, or grand mal, are the most common and severe type of systemic seizure, accounting for about 60% of cases of systemic seizures PGTC seizures are characterized by loss of consciousness and systemic convulsions, common seizuresymptoms are characterized by spitting white foam, double eyelids, twitching limbs, screaming and other serious will cause incontinence, persistent seizures and so on seizures are the result of neuronal stimulation and inhibition of imbalances in the brain, which can be triggered by a variety of neurochemical mechanisms, but little is known () Original source: NEW FINE GRANULE OF ANTI-EPILEPTIC DRUG FYCOMPA? LAUNCHED IN JAPAN.